Most neurotech companies have world-class research teams and a brand that reads like an academic paper. We build brand strategies that translate complex neuroscience into clear positioning that resonates with investors, enterprise buyers, and regulators alike.
The Problem
Your positioning sounds like every other neuroscience startup
When your website reads like a grant application, you blend in with hundreds of other neurotech companies saying the same things about 'proprietary algorithms' and 'novel approaches.' Enterprise buyers and investors scan dozens of decks a week. If your positioning doesn't differentiate in the first 30 seconds, you lose the meeting. This is especially acute in neurotech where the underlying science is genuinely hard to communicate without defaulting to jargon.
Investors don't understand what you actually do
Neurotech founders often come from research backgrounds where precision matters more than clarity. That instinct works in peer review but kills you in a fundraise. When your Series A deck requires a neuroscience glossary, you're losing capital to competitors with clearer stories. The gap between what your technology does and what people think it does is a brand problem, not a science problem.
Your brand can't keep up with your regulatory milestones
FDA clearance, breakthrough device designation, clinical trial results — these are inflection points that should reshape how the market perceives you. But most neurotech companies treat brand as a static asset built once at founding. Every regulatory milestone is a brand moment. If your positioning doesn't evolve with your clinical progress, you're leaving credibility and market attention on the table.
You're selling to both clinicians and C-suites with the same message
Neurotech buyers are uniquely bifurcated. The neurologist evaluating your device cares about signal quality and clinical evidence. The hospital CFO cares about reimbursement codes and ROI. Using one message for both audiences means you're convincing neither. Most neurotech companies default to the technical story because that's what the founding team knows, and the commercial audience tunes out.
How We Help
We start with a brand audit that maps your current positioning against the competitive set — not just other neurotech companies, but every alternative your buyer is considering, including doing nothing. We interview your customers, your investors, and your internal team to find the gaps between how you see yourselves and how the market sees you. This isn't a vibes exercise. It's a structured diagnostic that surfaces exactly where your brand is costing you deals.
From the audit, we build a positioning framework specific to your regulatory stage and target buyer. A pre-FDA neurotech company needs different brand architecture than one with 510(k) clearance selling into health systems. We define your category, your differentiation, and your proof points in language that works across investor decks, sales conversations, and clinical conferences.
We then develop your messaging hierarchy — the core narrative that connects your science to market outcomes, with modular layers for each audience. Your clinical audience gets evidence-first messaging. Your enterprise buyers get outcomes-first messaging. Your investors get trajectory-first messaging. Same brand, different entry points, all internally consistent.
The visual identity work follows the strategic foundation, not the other way around. We've seen too many neurotech companies spend six figures on a rebrand that looks great and says nothing. Every visual decision we make ties back to positioning — from how you visualize neural data to the tone of your photography. This is especially important in neurotech where the temptation to default to generic brain imagery is strong and counterproductive.
Execution includes brand guidelines built for a team that's actually going to use them. Not a 200-page PDF that sits in a shared drive. We build playbooks with templates for investor presentations, conference materials, website copy, and sales enablement that your team can run with. For neurotech companies, we include specific guidance on regulatory-compliant claims and how to talk about clinical data without making your legal team nervous.
We also build your brand measurement framework. Brand is often treated as unmeasurable, but we track share of voice in your category, message pull-through in press coverage, investor meeting conversion rates, and website engagement by audience segment. You'll know exactly what's working and what needs adjustment.
The engagement wraps with a 90-day roadmap for brand activation — the specific campaigns, content, and touchpoints that put your new positioning into market. We don't hand you a strategy deck and walk away. The roadmap includes owners, timelines, and success metrics so your team can execute independently.
What we deliver
- Brand positioning framework — competitive analysis, category definition, differentiation map, and proof point architecture
- Messaging hierarchy — core narrative plus audience-specific messaging for investors, enterprise buyers, and clinical stakeholders
- Visual identity system — logo refinement, color system, typography, data visualization guidelines, and photography direction
- Brand activation playbook — templates, regulatory-compliant claim guidelines, and 90-day go-to-market roadmap
In neurotech, the companies that win aren't the ones with the best science — they're the ones who can explain what their science means for the person writing the check. Brand strategy is the translation layer between your lab and your market.
Our Methodology
We run brand strategy as a 90-day sprint, not a six-month consulting engagement. The first 30 days are diagnostic: competitive audit, stakeholder interviews, and market analysis. We move fast because neurotech markets move fast — your next funding round or FDA milestone won't wait for a traditional branding timeline.
Days 31 through 60 are strategy and creative development. We present positioning options, pressure-test them against real buyer scenarios, and build the messaging and visual system in parallel. Neurotech founders are used to iterative development in their R&D process, and we apply the same discipline to brand work. Weekly reviews, rapid iteration, clear decision points.
The final 30 days are activation and handoff. We deploy the new brand across priority touchpoints, train your team on the system, and establish measurement baselines. Unlike traditional brand agencies that disappear after the logo reveal, we stay through the first activation cycle to make sure the strategy actually works in market. The 90-day model means you're not paying for idle time between review cycles — every week has a deliverable.
How We Work
The typical brand strategy engagement runs 90 days with a dedicated team of a strategist, a writer, and a designer. For neurotech clients, we often add a team member with healthcare or regulatory marketing experience. You'll have a single point of contact who runs the project and makes sure nothing falls through the cracks.
The cadence is weekly strategy sessions for the first month, shifting to bi-weekly reviews during creative development. We use shared workspaces so your team has visibility into progress at all times. Feedback cycles are 48 hours or less — we don't let work sit.
Your internal commitment is roughly 3-5 hours per week from your leadership team during the diagnostic phase, dropping to 1-2 hours during execution. We need access to your CEO or founder, your head of commercial, and ideally someone from your clinical or regulatory team. The more context we have, the sharper the output.
Clients should expect a brand system that their team can actually use, not a shelf piece. By day 90, your positioning is live, your team is trained, and your measurement framework is tracking results. Most clients see immediate improvements in investor meeting quality and sales conversation clarity.
- Clear market positioning that differentiates from competitors and resonates across investor, enterprise, and clinical audiences
- Consistent brand execution across all touchpoints with regulatory-compliant messaging guidelines
- Measurable improvements in investor engagement, sales pipeline quality, and brand awareness within target segments
If your neurotech company needs brand strategy leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does brand strategy cost for neurotech companies?
A full brand strategy engagement typically runs between $75K and $200K depending on scope. That includes positioning, messaging, visual identity, and activation planning. For context, most neurotech companies spend more than that on a single conference booth that communicates nothing memorable. The ROI shows up in shorter sales cycles, better investor conversations, and a team that can articulate what you do without a 20-minute preamble.
How long before we see results from brand strategy?
You'll have a complete brand system in 90 days. Measurable market impact typically shows within 90-180 days after activation — that's when you start seeing changes in investor meeting conversion, inbound quality, and sales cycle length. Brand is a compounding asset. The initial lift is noticeable, but the real value builds over 6-12 months as your positioning gets reinforced across every touchpoint.
How does the brand strategy team integrate with our existing staff?
We work directly with your leadership team and whoever owns marketing, even if that's just one person. For neurotech companies without a full marketing function, we often serve as the interim brand team and build the playbooks so you can hire into a clear structure later. We plug into your existing tools — Slack, Notion, whatever you use — and run the project like we're part of your team, not an outside agency delivering work over the wall.
What makes Winston Francois different from a traditional brand strategy agency?
Most brand agencies start with aesthetics and work backward to strategy. We start with your commercial reality — who's buying, what's blocking them, and what your regulatory timeline looks like — and build the brand to serve those goals. We also move at startup speed, not agency speed. Ninety days, not nine months. And we stay through activation, so you're not left holding a beautiful strategy deck with no idea how to implement it.
How do you measure ROI from a brand strategy engagement?
We set up measurement from day one. Core metrics include investor meeting-to-next-step conversion rate, sales cycle length, inbound lead quality, website engagement by audience segment, and share of voice in your category. We establish baselines during the diagnostic phase so you have a clear before-and-after. Brand ROI isn't always immediate, but it is measurable if you're tracking the right things.
What type of neurotech company is the right fit for this service?
The sweet spot is Series A through Series C neurotech companies that have proven technology and are entering or scaling their commercial phase. If you're pre-revenue with a working prototype and an upcoming fundraise, brand strategy will directly impact your raise. If you're post-FDA-clearance and building a sales team, clear positioning is the foundation everything else runs on. Very early-stage companies still in pure R&D mode may be too early for a full brand engagement.
